D Warren

580 total citations
12 papers, 364 citations indexed

About

D Warren is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, D Warren has authored 12 papers receiving a total of 364 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Hematology, 5 papers in Oncology and 4 papers in Molecular Biology. Recurrent topics in D Warren's work include Chronic Lymphocytic Leukemia Research (3 papers), HER2/EGFR in Cancer Research (3 papers) and Cancer Treatment and Pharmacology (3 papers). D Warren is often cited by papers focused on Chronic Lymphocytic Leukemia Research (3 papers), HER2/EGFR in Cancer Research (3 papers) and Cancer Treatment and Pharmacology (3 papers). D Warren collaborates with scholars based in United States and United Kingdom. D Warren's co-authors include Lois Ayash, E Reich, Gary N. Schwartz, Anthony Elias, C Lynch, Karen H. Antman, Lowell E. Schnipper, Catherine Wheeler, E Frei and C Wheeler and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Leukemia.

In The Last Decade

D Warren

12 papers receiving 350 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
D Warren United States 7 260 138 105 75 74 12 364
E Reich United States 7 266 1.0× 137 1.0× 112 1.1× 52 0.7× 77 1.0× 7 353
C Lynch United States 6 324 1.2× 104 0.8× 246 2.3× 49 0.7× 73 1.0× 6 460
S Wolff United States 4 307 1.2× 107 0.8× 99 0.9× 74 1.0× 48 0.6× 6 408
Caroline Girouard Canada 9 217 0.8× 103 0.7× 107 1.0× 168 2.2× 56 0.8× 9 367
M. H. Purdy United States 4 224 0.9× 96 0.7× 246 2.3× 39 0.5× 48 0.6× 7 439
J.M. Extra France 11 306 1.2× 175 1.3× 25 0.2× 101 1.3× 63 0.9× 33 430
Ricardo Alvarez United States 11 133 0.5× 58 0.4× 72 0.7× 65 0.9× 98 1.3× 20 374
Thilo Zander Switzerland 10 143 0.6× 56 0.4× 61 0.6× 70 0.9× 112 1.5× 25 308
Jake Allred United States 8 258 1.0× 49 0.4× 46 0.4× 83 1.1× 57 0.8× 13 373
M.C. Cox United States 10 180 0.7× 74 0.5× 50 0.5× 117 1.6× 177 2.4× 23 429

Countries citing papers authored by D Warren

Since Specialization
Citations

This map shows the geographic impact of D Warren's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D Warren with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D Warren more than expected).

Fields of papers citing papers by D Warren

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by D Warren. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D Warren. The network helps show where D Warren may publish in the future.

Co-authorship network of co-authors of D Warren

This figure shows the co-authorship network connecting the top 25 collaborators of D Warren. A scholar is included among the top collaborators of D Warren based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with D Warren. D Warren is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
Ghobrial, Irene M., Robert Redd, Philippe Armand, et al.. (2015). Phase I/II trial of everolimus in combination with bortezomib and rituximab (RVR) in relapsed/refractory Waldenstrom macroglobulinemia. Leukemia. 29(12). 2338–2346. 26 indexed citations
2.
Leduc, Renee, Marybeth Nelson, Amy Sam, et al.. (2009). A573 Phase I Trial of CCI-779 and Weekly Bortezomib in Relapsed and/or Refractory Multiple Myeloma. Clinical Lymphoma & Myeloma. 9. S86–S86. 1 indexed citations
3.
Ghobrial, Irene M., Swaminathan P. Iyer, Stacey Chuma, et al.. (2009). Phase II trial of combination of bortezomib and rituximab in relapsed and/or refractory Waldenstrom macroglobulinemia. Journal of Clinical Oncology. 27(15_suppl). 8535–8535. 2 indexed citations
4.
Schlossman, R, Stacey Chuma, Renee Leduc, et al.. (2009). A535 Phase II Trial of Bortezomib and Rituximab in Relapsed/Refractory Waldenström Macroglobulinemia. Clinical Lymphoma & Myeloma. 9. S83–S84. 1 indexed citations
5.
Richardson, Paul G., Robert J. Soiffer, Joseph H. Antin, et al.. (2006). Defibrotide (DF) for the Treatment of Severe Veno-Occlusive Disease (sVOD) and Multi-Organ Failure (MOF) Post SCT: Final Results of a Multi-Center, Randomized, Dose-Finding Trial.. Blood. 108(11). 43–43. 6 indexed citations
6.
Richardson, Paul G., David Avigan, Joseph G. Ibrahim, et al.. (2001). A short course of induction chemotherapy followed by two cycles of high-dose chemotherapy with stem cell rescue for chemotherapy naive metastatic breast cancer: sequential phase I/II studies. Bone Marrow Transplantation. 28(5). 447–454. 4 indexed citations
7.
Richardson, Paul G., David Avigan, Joseph G. Ibrahim, et al.. (2001). A short course of induction chemotherapy followed by two cycles of high-dose chemotherapy with stem cell rescue for chemotherapy naive metastatic breast cancer. Bone Marrow Transplantation. 27(3). 269–278. 11 indexed citations
8.
Ayash, Lois, Anthony Elias, Joseph G. Ibrahim, et al.. (1998). High-dose multimodality therapy with autologous stem-cell support for stage IIIB breast carcinoma.. Journal of Clinical Oncology. 16(3). 1000–1007. 50 indexed citations
9.
Elias, AD, Catherine Wheeler, Lois Ayash, et al.. (1998). Dose escalation of the hypoxic cell sensitizer etanidazole combined with ifosfamide, carboplatin, etoposide, and autologous hematopoietic stem cell support.. PubMed. 4(6). 1443–9. 4 indexed citations
10.
11.
Ayash, Lois, C Wheeler, Diane L. Fairclough, et al.. (1995). Prognostic factors for prolonged progression-free survival with high-dose chemotherapy with autologous stem-cell support for advanced breast cancer.. Journal of Clinical Oncology. 13(8). 2043–2049. 99 indexed citations
12.
Ayash, Lois, Anthony Elias, Catherine Wheeler, et al.. (1994). Double dose-intensive chemotherapy with autologous marrow and peripheral-blood progenitor-cell support for metastatic breast cancer: a feasibility study.. Journal of Clinical Oncology. 12(1). 37–44. 117 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by E Reich Breakdown of academic impact, for papers by C Lynch Breakdown of academic impact, for papers by S Wolff Breakdown of academic impact, for papers by Caroline Girouard Breakdown of academic impact, for papers by M. H. Purdy Breakdown of academic impact, for papers by J.M. Extra Breakdown of academic impact, for papers by Ricardo Alvarez Breakdown of academic impact, for papers by Thilo Zander Breakdown of academic impact, for papers by Jake Allred Breakdown of academic impact, for papers by M.C. Cox
Rankless by CCL
2026